Ascentage Pharma to Present Four Key Preclinical Studies at AACR Annual Meeting 2026

Ascentage Pharma Group International (HKEX: 6855) has announced that four preclinical abstracts from its innovative oncology pipeline have been selected for poster presentations at the prestigious American Association of Cancer Research (AACR) Annual Meeting 2026, scheduled for April 17-22, 2026, in San Diego, California, USA.

Key Highlights of the Announcement

• Four preclinical studies from Ascentage’s pipeline will be presented at AACR 2026, a major international cancer conference.
• These studies feature three novel drug candidates targeting various cancer indications:
  • Olverembatinib (HQP1351): BCR-ABL tyrosine kinase inhibitor, a multitarget kinase inhibitor.
  • APG-2449: FAK/ALK/ROS1 tyrosine kinase inhibitor.
  • APG-5918: EED inhibitor targeting epigenetic mechanisms in cancer.
• The selection of these abstracts indicates ongoing scientific progress and demonstrates the potential of Ascentage Pharma’s pipeline to address significant unmet needs in oncology.
• These presentations could attract attention from partners, investors, and the scientific community, potentially impacting the company’s valuation and share price.

Details of the Four Preclinical Studies

1. Olverembatinib (HQP1351) in Endometrial Carcinoma (EC):
   • Study shows that olverembatinib is efficacious and synergizes with chemotherapy in preclinical models of endometrial carcinoma.
   • Poster Session: Experimental and Molecular Therapeutics, “Novel Antitumor Agents 2”
   • Presentation Time: April 21, 2026, 9:00 AM – 12:00 PM PDT (April 22, 2026, 0:00 AM – 3:00 AM Beijing Time)
   • Abstract Number: 4583
2. Olverembatinib (HQP1351) and BTK Inhibitor Acalabrutinib in Mantle Cell Lymphoma (MCL):
   • Preclinical data demonstrate that olverembatinib is efficacious and synergizes with acalabrutinib (a BTK inhibitor) in MCL models.
   • Poster Session: Experimental and Molecular Therapeutics, “Tyrosine Kinase, Phosphatase, and Other Inhibitors”
   • Presentation Time: April 21, 2026, 2:00 PM – 5:00 PM PDT (April 22, 2026, 5:00 AM – 8:00 AM Beijing Time)
   • Abstract Number: 5875
3. APG-2449 in BRAF V600E-Mutant Tumor Models:
   • Findings show that FAK inhibition by APG-2449 enhances the antitumor activity of MAPK pathway blockade, suggesting potential in BRAF V600E-mutant cancers.
   • Poster Session: Experimental and Molecular Therapeutics, “Targeting Drug Resistance 1: Apoptosis and Autophagy”
   • Presentation Time: April 20, 2026, 9:00 AM – 12:00 PM PDT (April 21, 2026, 0:00 AM – 3:00 AM Beijing Time)
   • Abstract Number: 1858
4. APG-5918 in Small-Cell Lung Cancer (SCLC):
   • Study shows that the EED inhibitor APG-5918 synergizes with topoisomerase I inhibitors in SCLC models by epigenetic priming of chemosensitivity.
   • Poster Session: Experimental and Molecular Therapeutics, “Epigenetic Modulators 1”
   • Presentation Time: April 21, 2026, 9:00 AM – 12:00 PM PDT (April 22, 2026, 0:00 AM – 3:00 AM Beijing Time)
   • Abstract Number: 4500

Significance for Shareholders

• Potential Price-Sensitive Information: Presentation of positive preclinical data at a major international conference often increases visibility and credibility, potentially attracting new investors and partnership opportunities.
• These studies focus on significant, high-value indications (endometrial carcinoma, mantle cell lymphoma, BRAF mutant tumors, and small-cell lung cancer), representing large market opportunities if the drugs advance successfully through clinical development.
• Caution: The company specifically notes that there is no guarantee APG-2449 and APG-5918 will be successfully developed or commercialized. Investors should remain aware of the risks associated with preclinical-stage assets and the inherent uncertainty in drug development.
• The company’s progress in multiple programs may be seen as a sign of robust R&D productivity, which could positively influence market sentiment and share price.
• Updates from these studies could serve as important future catalysts, especially if they translate into clinical trials or attract licensing/partnering interest.

Company Leadership and Governance

The announcement was made by Dr. Yang Dajun, Chairman and Executive Director. The Board includes leading figures with deep expertise, including independent non-executive directors who satisfy both Hong Kong and U.S. governance requirements, enhancing the company’s credibility with global investors.

Disclaimer

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Although the preclinical data presented may indicate scientific progress, there is no assurance that any of Ascentage Pharma’s pipeline products will successfully complete development or gain regulatory approval. Investors should conduct their own due diligence and consult with professional advisors before making any investment decisions. The company has explicitly cautioned that products such as APG-2449 and APG-5918 may not ultimately be successfully developed or marketed.

View ASCENTAGE-B Historical chart here